That means Vioxx results cannot automatically be extended to Celebrex and Bextra, which are in the Cox-2 classification with Vioxx but are not identical to it.
Merck, which knew Vioxx was in competition with similar drugs, then conducted further trials, largely to find out if Vioxx could be legitimately recommended for other conditions.
Merck removed Vioxx from sale Sept. 28 after seeing an increased risk of "serious cardiovascular events," the FDA said, including heart attacks and strokes.
Merck took the drastic step of pulling Vioxx because its research showed it caused increased risk of heart attack.
